First-Ever Clinical Trial Demonstrates Safety, Molecular Readout and Promise of Pre- and Post-Surgery Immunotherapy Combination for Patients with Operable Mesothelioma | Naviance

First-Ever Clinical Trial Demonstrates Safety, Molecular Readout and Promise of Pre- and Post-Surgery Immunotherapy Combination for Patients with Operable Mesothelioma

First-Ever Clinical Trial Demonstrates Safety, Molecular Readout and Promise of Pre- and Post-Surgery Immunotherapy Combination for Patients with Operable Mesothelioma

A novel treatment approach using combination immunotherapy before and after surgery shows promise for patients with operable mesothelioma, according to a new study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

LEARN MORE

Recent Posts

Prostate Cancer: Advancements in Screening Experimental KRAS Vaccine Generates Immune Response Against Pancreatic Cancer in People at High Risk Newly Identified Inhibitors May Boost Chemotherapy Drug’s Ability to Fight Treatment-Resistant Cancers Virtual Tumor Predict Response to Liver Cancer Immunotherapy Ovarian Cancer Researcher Wins Prestigious Lotus Award Blocking Energy Metabolism May Help Treat Aggressive Pediatric Brain Tumor This new drug could change how we treat one of the deadliest cancers Inherited Long Telomeres May Drive Broad Risk for Lymphoid Cancers How a Division I athlete who never smoked turned his stage 4 ALK+ lung cancer diagnosis into a fight for a cure